Skip to main content
S&P 5007,520.93-0.38%DOW52,231.89-0.30%NASDAQ25,065.88-0.74%BTC$73,985.00-0.36%ETH$2,055.09-1.66%GOLD$4,054.00+0.59%OIL$87.04+1.16%
Smart Investors Daily
SID Premium
LC

AMEX · LCTX

Lineage Cell Therapeutics, Inc.

Healthcare · Biotechnology

$1.04

Down-$0.04 (-3.70%)

Updated Nov 11, 2026, 12:12 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
396.81M
P/E ratio
-5.83
Dividend yield
0.00%
52-week range
$0.88 – $1.86
Volume
1.15M
Avg. volume
1.99M

Price performance · LCTX

LCTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

LCTX closed at $1.04 after 21 trading sessions, up 14.50% for the selected period.

Last close
$1.04
Period change
+14.50%
Period low
$0.91
Period high
$1.08
Daily close
View OHLC price history
LCTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$1.06$1.07$1.03$1.041.15M
Nov 9, 2026$1.01$1.09$0.9963$1.08974.45K
Nov 6, 2026$0.9644$1.03$0.9644$1.021.03M
Nov 5, 2026$1.03$1.03$0.9664$0.98312.35M
Nov 4, 2026$1.03$1.065$1.0118$1.03965.03K
Nov 3, 2026$1.02$1.035$0.9875$1.01919.89K
Nov 2, 2026$1.01$1.02$0.9753$1.011.72M
Oct 30, 2026$1.04$1.05$0.982$1.001.17M
Oct 29, 2026$1.05$1.06$1.02$1.03937.73K
Oct 28, 2026$1.03$1.045$1.01$1.041.08M
Oct 27, 2026$0.9925$1.04$0.9751$1.031.2M
Oct 26, 2026$1.00$1.01$0.9616$0.99691.91M
Oct 23, 2026$0.9657$1.015$0.9436$1.001.15M
Oct 22, 2026$0.9483$1.01$0.9401$0.9851.35M
Oct 21, 2026$0.9865$0.9903$0.9376$0.95151.22M
Oct 20, 2026$0.9508$1.01$0.9508$0.97261.63M
Oct 19, 2026$0.9809$0.9997$0.94$0.9528955.55K
Oct 16, 2026$0.98$1.00$0.96$0.97831.31M
Oct 15, 2026$0.9212$0.9994$0.918$0.99031.42M
Oct 14, 2026$0.9142$0.94$0.8902$0.91752.2M
Oct 13, 2026$0.95$0.97$0.895$0.90831.78M

Latest LCTX news

The latest Smart Investors Daily articles mentioning LCTX.

Stock researchCompany · Overview

LCTX research

Overview

Company profile and research snapshot.

Company profile

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
LCTX recent ratings
DateFirmRatingTarget
Jul 14, 2026HC Wainwright & Co.Buy—
May 4, 2026D. Boral CapitalBuy—
Apr 28, 2026Canaccord GenuityBuy—
Mar 25, 2026B. Riley SecuritiesBuy—
Mar 24, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Lineage Provides Update on ReSonance® Program for Hearing Loss

CARLSBAD, Calif., October 29, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today provided an update on ReSonance (ANP1), the Company’s first internally-developed cell transplant program, for the treatment of hearing loss built on its patented and proprietary AlloSCOPE™ manufacturing platform, currently being developed under a research colla

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By